How have the shares performed?
CASI Pharmaceuticals Inc. (CASI) saw downtrend of -4.19% in the recent trading with $3.20 being its most recent. The current price level -17.95% lower than the highest price of $3.90 marked by the stock while trading over the past 52-weeks, whereas it is 178.26% higher than the lowest price of $1.15 the company dropped to over past 52-weeks. The latest news story on CASI appeared in PR Newswire under the title “CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients” on Jan-28-21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Squeezing the time span to 30 day period shows us the stock is currently trading -17.95% below one month high and is +10.73% above of the lowest during that time. Looking into the simple moving average, CASI Pharmaceuticals Inc. (CASI)’s stock stands at a SMA-50 of $2.98 while that of 5-day is reading $3.39.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and CASI’s SMA-200 as of now is $2.26.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
CASI Pharmaceuticals Inc. Earnings – What Happened With CASI
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. CASI Pharmaceuticals Inc. (CASI) last released financial results for the quarter that ended 9/29/2020, posting a surprise factor of -180.00% for net revenue. During the reported three-month period, company’s sales were $4.21 billion while analysts on average were estimating the same to be $4.45 million.
CASI – CASI Pharmaceuticals Inc. Stock Earnings Estimates
The perspective of CASI Pharmaceuticals Inc. (NASDAQ:CASI)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.05 for stock’s EPS in the current quarter. 2 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.14.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 117.94 million. CASI does have institutional investors; and they hold 32.30% of the stock.
CASI Pharmaceuticals Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 3 new insider purchases involving 6,000 shares. On the other hand, CASI declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Sep 29, 2020, IDG-Accel China Growth Fund III Associates, LP was the top most holder in CASI Pharmaceuticals Inc. (NASDAQ:CASI) with an ownership of 7.97 million shares of the company or 6.43% of the stake worth $12.2 million. The filing also reveals Federated Hermes, Inc. as the second largest holder in the company with a control over 5.57% of the outstanding shares. Its stake is worth $10.56 million for having 6.9 million shares in hand.
Consonance Capital Management LP also came holding a key position in the company during the recent quarter and it now holds 5.29% of the outstanding shares. With this there are now 94 institutions which have possession in CASI’s shares.
Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by CASI Pharmaceuticals Inc. was 7.74 while posting a debt to equity ratio of 0.00. The count was 1.40 for long-term debt to equity ratio.
CASI Pharmaceuticals Inc.’s return on equity, or ROE, is -63.00%, compared to the industry average of -46.13% for Healthcare – Biotechnology. Although this indicates that CASI fails to use its equity well, the metric will vary significantly depending on the industry.
